Astellas surpassed market expectations in its third-quarter fiscal year 2025 results, as first-in-class cancer drug Vyloy defied a trial setback to deliver quadrupled sales. | Astellas surpassed ...

In this phase 2 study, researchers explored whether fecal microbiota transplant could overcome resistance to immune checkpoint inhibition.

From penetrating solid tumors to new success rates for de novo design, the next wave of antibody therapies aims to transform the clinic.

Thank you and good morning everyone. With me this morning with prepared remarks are Christopher Boerner, our board chair and ...

Caring for someone with advanced NSCLC is challenging, and support is available for both caregivers and patients. As a caregiver, it is just as important to take time for self-care as it is to tend to ...